vs
MESA LABORATORIES INC（MLAB）与PDF SOLUTIONS INC（PDFS）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是PDF SOLUTIONS INC的1.0倍（$65.1M vs $62.4M），MESA LABORATORIES INC净利率更高（5.6% vs -0.1%，领先5.7%），PDF SOLUTIONS INC同比增速更快（24.6% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $7.5M），过去两年PDF SOLUTIONS INC的营收复合增速更高（22.9% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
PDF Solutions Inc是一家总部位于美国加利福尼亚州圣克拉拉的跨国企业，主营软件业务与工程技术服务，目前在纳斯达克交易所挂牌上市，股票代码为PDFS。
MLAB vs PDFS — 直观对比
营收规模更大
MLAB
是对方的1.0倍
$62.4M
营收增速更快
PDFS
高出21.0%
3.6%
净利率更高
MLAB
高出5.7%
-0.1%
自由现金流更多
MLAB
多$10.5M
$7.5M
两年增速更快
PDFS
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $62.4M |
| 净利润 | $3.6M | $-48.0K |
| 毛利率 | 64.2% | 72.9% |
| 营业利润率 | 12.2% | 5.5% |
| 净利率 | 5.6% | -0.1% |
| 营收同比 | 3.6% | 24.6% |
| 净利润同比 | 316.6% | -108.9% |
| 每股收益（稀释后） | $0.65 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABPDFS
| Q4 25 | $65.1M | $62.4M | ||
| Q3 25 | $60.7M | $57.1M | ||
| Q2 25 | $59.5M | $51.7M | ||
| Q1 25 | $62.1M | $47.8M | ||
| Q4 24 | $62.8M | $50.1M | ||
| Q3 24 | $57.8M | $46.4M | ||
| Q2 24 | $58.2M | $41.7M | ||
| Q1 24 | $58.9M | $41.3M |
净利润MLABPDFS
| Q4 25 | $3.6M | $-48.0K | ||
| Q3 25 | $2.5M | $1.3M | ||
| Q2 25 | $4.7M | $1.1M | ||
| Q1 25 | $-7.1M | $-3.0M | ||
| Q4 24 | $-1.7M | $539.0K | ||
| Q3 24 | $3.4M | $2.2M | ||
| Q2 24 | $3.4M | $1.7M | ||
| Q1 24 | $-254.6M | $-393.0K |
毛利率MLABPDFS
| Q4 25 | 64.2% | 72.9% | ||
| Q3 25 | 61.5% | 72.3% | ||
| Q2 25 | 62.0% | 71.2% | ||
| Q1 25 | 61.8% | 72.9% | ||
| Q4 24 | 63.3% | 68.3% | ||
| Q3 24 | 61.3% | 73.1% | ||
| Q2 24 | 64.0% | 70.6% | ||
| Q1 24 | 62.1% | 67.3% |
营业利润率MLABPDFS
| Q4 25 | 12.2% | 5.5% | ||
| Q3 25 | 7.8% | 8.5% | ||
| Q2 25 | 5.1% | 2.2% | ||
| Q1 25 | 2.4% | -7.4% | ||
| Q4 24 | 9.2% | 1.0% | ||
| Q3 24 | 6.1% | 4.6% | ||
| Q2 24 | 9.6% | 0.6% | ||
| Q1 24 | -460.6% | -4.7% |
净利率MLABPDFS
| Q4 25 | 5.6% | -0.1% | ||
| Q3 25 | 4.1% | 2.3% | ||
| Q2 25 | 8.0% | 2.2% | ||
| Q1 25 | -11.4% | -6.3% | ||
| Q4 24 | -2.7% | 1.1% | ||
| Q3 24 | 5.9% | 4.8% | ||
| Q2 24 | 5.8% | 4.1% | ||
| Q1 24 | -432.2% | -1.0% |
每股收益（稀释后）MLABPDFS
| Q4 25 | $0.65 | $0.00 | ||
| Q3 25 | $0.45 | $0.03 | ||
| Q2 25 | $0.85 | $0.03 | ||
| Q1 25 | $-1.30 | $-0.08 | ||
| Q4 24 | $-0.31 | $0.01 | ||
| Q3 24 | $0.63 | $0.06 | ||
| Q2 24 | $0.62 | $0.04 | ||
| Q1 24 | $-47.26 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $42.2M |
| 总债务越低越好 | $68.4M | $67.0M |
| 股东权益账面价值 | $186.7M | $271.0M |
| 总资产 | $434.8M | $418.7M |
| 负债/权益比越低杠杆越低 | 0.37× | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资MLABPDFS
| Q4 25 | $29.0M | $42.2M | ||
| Q3 25 | $20.4M | $35.9M | ||
| Q2 25 | $21.3M | $40.4M | ||
| Q1 25 | $27.3M | $54.1M | ||
| Q4 24 | $27.3M | $114.9M | ||
| Q3 24 | $24.3M | $120.2M | ||
| Q2 24 | $28.5M | $117.9M | ||
| Q1 24 | $28.2M | $122.9M |
总债务MLABPDFS
| Q4 25 | $68.4M | $67.0M | ||
| Q3 25 | $69.4M | $67.6M | ||
| Q2 25 | $70.3M | $68.1M | ||
| Q1 25 | $71.3M | $68.7M | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABPDFS
| Q4 25 | $186.7M | $271.0M | ||
| Q3 25 | $178.5M | $264.4M | ||
| Q2 25 | $172.5M | $257.5M | ||
| Q1 25 | $159.8M | $249.0M | ||
| Q4 24 | $155.2M | $246.0M | ||
| Q3 24 | $161.5M | $240.5M | ||
| Q2 24 | $150.7M | $232.2M | ||
| Q1 24 | $145.4M | $225.4M |
总资产MLABPDFS
| Q4 25 | $434.8M | $418.7M | ||
| Q3 25 | $430.4M | $406.4M | ||
| Q2 25 | $435.7M | $391.1M | ||
| Q1 25 | $433.3M | $390.0M | ||
| Q4 24 | $433.3M | $315.3M | ||
| Q3 24 | $454.1M | $307.4M | ||
| Q2 24 | $440.4M | $298.0M | ||
| Q1 24 | $446.8M | $286.8M |
负债/权益比MLABPDFS
| Q4 25 | 0.37× | 0.25× | ||
| Q3 25 | 0.39× | 0.26× | ||
| Q2 25 | 0.41× | 0.26× | ||
| Q1 25 | 0.45× | 0.28× | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $17.3M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $7.5M |
| 自由现金流率自由现金流/营收 | 27.7% | 12.1% |
| 资本支出强度资本支出/营收 | 1.1% | 15.7% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $-8.6M |
8季度趋势，按日历期对齐
经营现金流MLABPDFS
| Q4 25 | $18.8M | $17.3M | ||
| Q3 25 | $8.2M | $3.3M | ||
| Q2 25 | $1.9M | $-5.2M | ||
| Q1 25 | $12.7M | $8.6M | ||
| Q4 24 | $18.1M | $1.6M | ||
| Q3 24 | $5.3M | $9.3M | ||
| Q2 24 | $10.7M | $684.0K | ||
| Q1 24 | $12.9M | $-1.9M |
自由现金流MLABPDFS
| Q4 25 | $18.0M | $7.5M | ||
| Q3 25 | $7.1M | $-2.9M | ||
| Q2 25 | $884.0K | $-13.8M | ||
| Q1 25 | $11.9M | $535.0K | ||
| Q4 24 | $17.3M | $-4.0M | ||
| Q3 24 | $3.5M | $5.1M | ||
| Q2 24 | $9.9M | $-4.6M | ||
| Q1 24 | $12.3M | $-3.9M |
自由现金流率MLABPDFS
| Q4 25 | 27.7% | 12.1% | ||
| Q3 25 | 11.7% | -5.1% | ||
| Q2 25 | 1.5% | -26.6% | ||
| Q1 25 | 19.2% | 1.1% | ||
| Q4 24 | 27.6% | -8.0% | ||
| Q3 24 | 6.0% | 11.0% | ||
| Q2 24 | 16.9% | -11.1% | ||
| Q1 24 | 21.0% | -9.4% |
资本支出强度MLABPDFS
| Q4 25 | 1.1% | 15.7% | ||
| Q3 25 | 1.8% | 10.8% | ||
| Q2 25 | 1.7% | 16.5% | ||
| Q1 25 | 1.2% | 17.0% | ||
| Q4 24 | 1.3% | 11.3% | ||
| Q3 24 | 3.1% | 9.0% | ||
| Q2 24 | 1.5% | 12.8% | ||
| Q1 24 | 0.9% | 4.9% |
现金转化率MLABPDFS
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | 2.54× | ||
| Q2 25 | 0.40× | -4.55× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.98× | ||
| Q3 24 | 1.54× | 4.20× | ||
| Q2 24 | 3.17× | 0.40× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
PDFS
| Volumebased | $38.0M | 61% |
| Other | $24.4M | 39% |
